.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Fuji
Cipla
Chinese Patent Office
Daiichi Sankyo
Julphar
Healthtrust
Deloitte
Merck
Cantor Fitzgerald

Generated: December 16, 2017

DrugPatentWatch Database Preview

Tolmar Company Profile

« Back to Dashboard

What is the competitive landscape for TOLMAR, and when can generic versions of TOLMAR drugs launch?

TOLMAR has thirty approved drugs.

There are nine US patents protecting TOLMAR drugs.

There are sixty-seven patent family members on TOLMAR drugs in twenty-six countries and twenty-one supplementary protection certificates in seven countries.

Summary for Tolmar

International Patents:67
US Patents:9
Tradenames:21
Ingredients:21
NDAs:30
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
TolmarADAPALENEadapaleneGEL;TOPICAL200298-001Jun 14, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
TolmarCLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDEbenzoyl peroxide; clindamycin phosphateGEL;TOPICAL204087-001Jun 27, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
TolmarNAFTIFINE HYDROCHLORIDEnaftifine hydrochlorideCREAM;TOPICAL206960-001Apr 10, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004RXYesYes► Subscribe► Subscribe► Subscribe
TolmarMOMETASONE FUROATEmometasone furoateCREAM;TOPICAL076591-001Apr 18, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021379-001Jul 24, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
TolmarCLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDEbenzoyl peroxide; clindamycin phosphateGEL;TOPICAL203688-001Aug 25, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
TolmarLIDOCAINE AND PRILOCAINElidocaine; prilocaineCREAM;TOPICAL076320-001Aug 27, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021343-001Jan 23, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
TolmarCALCIPOTRIENEcalcipotrieneCREAM;TOPICAL200935-001May 30, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tolmar

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021343-001Jan 23, 2002► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021488-001Feb 13, 2003► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021379-001Jul 24, 2002► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021379-001Jul 24, 2002► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021488-001Feb 13, 2003► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021379-001Jul 24, 2002► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021488-001Feb 13, 2003► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021379-001Jul 24, 2002► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021488-001Feb 13, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tolmar

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,314 Controlled release liquid delivery compositions with low initial drug burst► Subscribe
6,630,155 Controlled release liquid delivery compositions with low initial drug burst► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tolmar Drugs

Country Document Number Estimated Expiration
Australia2010201645► Subscribe
Australia2006241376► Subscribe
Australia9293101► Subscribe
Australia2001292931► Subscribe
Japan6061823► Subscribe
Austria285261► Subscribe
South Africa200302944► Subscribe
Germany60141421► Subscribe
Japan2004510807► Subscribe
Slovakia5152003► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tolmar Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0014France► SubscribePRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
C/GB99/003United Kingdom► SubscribePRODUCT NAME: IMIQUIMOD; REGISTERED: UK EU/1/98/080/001 19980918
C0024France► SubscribePRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
00C/032Belgium► SubscribePRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
C0042Belgium► SubscribePRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Healthtrust
US Army
Fuji
Queensland Health
Merck
Cerilliant
US Department of Justice
QuintilesIMS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot